Senolytic therapy in mild Alzheimer’s disease shows safety in phase I trial

Researchers conducted the phase 1 trial of orally-administered senolytic therapy comprising quercetin (Q) and dasatinib (D) for symptomatic and early-stage Alzheimer’s disease (AD) patients.

Pablo Zuanic On Trade To Black To Talk Cannabis Reports

Welcome back to the Trade To Black Podcast! In today’s live streamed episode, we’ll be talking about some cannabis and psychedelic news, including what’s happening

January 18, 2024

Janssen’s BALVERSA gets EC approval for urothelial carcinoma

In a Phase III trial, erdafitinib treatment showed a median progression-free survival of 5.6 months versus 2.7 months for chemotherapy. Credit: MattL_Images/Shutterstock. The European Commission

August 26, 2024

Precise intensity-modulated radiotherapy outperforms 3D-CRT in advanced lung cancer

Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the more precise intensity-modulated

June 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.